Method for predicting cardiovascular events

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S803000, C435S967000, C436S501000, C436S008000, C436S093000, C436S098000, C436S129000, C436S131000, C436S161000, C436S164000, C436S172000, C436S804000, C436S811000, C436S815000, C424S009200, C514S165000, C548S318100, C548S318500, C548S347100, C549S292000, C549S427000, C703S002000

Reexamination Certificate

active

07081347

ABSTRACT:
A method for assessing aspirin resistance and relative risk of a cardiovascular event in a patient taking aspirin is provided. The concentration of 11-dehydro-thromboxane B2 in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro-thromboxane B2 that falls within the second, third, or fourth quartile is indicative of aspirin resistance and an elevated risk of a recurrent cardiovascular event.

REFERENCES:
patent: 5240917 (1993-08-01), Keimowitz et al.
patent: 2003/0124615 (2003-07-01), Ens
patent: 01013459 (1989-01-01), None
patent: 01 31052 (2001-05-01), None
Cipollone, F., et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in servere unstable angina. Circulation 2000; 102:1007-1013.
Encyclopedia of Biostatistics, Armitage & Colton, Eds. (1998) (relevant portions attached).
Strongin W. Sensitivity, specificity, and predictive value of diagnostic tests: definitions and clinical applications. Laboratory Diagnosis of Viral Infections, pp. 211-219, 2d. Ed. (1992).
Cipollone, F. et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. CIRCULATION. 1997;96:1109-1116, (pp. 1-15 Downloaded From Internet).
Database Internet 'Online! 2003 Cayman Chemical Inc: “519501 11 dehydro thromboxane assay” retieved from www.caymanchem.com XP002262581 abstract.
Eikelboom et al., “Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events”, Circulation 105:1650-1655, 2002, XP002262579.
Hayashi et al., “Enzyme Immunoassay of Thromboxane B2”, Biochimica et Biophysica Acta 750:322-329, 1983, XP009020472.
Reinke et al, “Development of an Enzyme-Linked Immunosorbent Assay of Thromboxane B2Using a Monoclonal Antibody”, Prostaglandins 37:577-586, 1989, XP009020476.
Eikelboom et al., “Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events”, Circulation 105:1650-1655, 2002.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for predicting cardiovascular events does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for predicting cardiovascular events, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for predicting cardiovascular events will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3583289

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.